Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13219550 | 0.83 | KMT2A (0.78) | MEN1KMT2APOLBRAB9AALDH1A1 | |
| SCHEMBL23801091 | 0.82 | MEN1 (0.60) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL755125 | 0.82 | MEN1 (0.60) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL8174177 | 0.81 | SMN1; SMN2 (0.57) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL9010787 | 0.81 | MEN1 (0.72) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL18094478 | 0.81 | MEN1 (0.58) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL20894915 | 0.80 | CYP1A2 (0.62) | MEN1KMT2ALMNARAB9AALDH1A1 | |
| SCHEMBL13015261 | 0.79 | MEN1 (0.56) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL9010888 | 0.79 | MEN1 (0.56) | MEN1KMT2ALMNAPOLBALOX15 | |
| SCHEMBL10053368 | 0.78 | MEN1 (0.55) | MEN1KMT2ALMNAPOLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2020-04-02 | — | — | US | disclosed |
| US-10246469-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-07 | — | — | US | disclosed |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS | 2017-05-25 | — | — | US | disclosed |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS | 2017-05-25 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | MEN1 4864/4885KMT2A 2483/4885LMNA 4425/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | MEN1 768/4885KMT2A 771/4885LMNA 637/4885 |
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | MEN1 4/4885KMT2A 3694/4885LMNA 1358/4885 |
| US-10246469-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | MEN1 4864/4885KMT2A 2483/4885LMNA 4425/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | MEN1 3743/4885KMT2A 2442/4885LMNA 2324/4885 |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | MEN1 4/4885KMT2A 3776/4885LMNA 1367/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | MEN1 2509/4885KMT2A 1948/4885LMNA 3803/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | MEN1 635/4885KMT2A 741/4885LMNA 620/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | MEN1 725/4885KMT2A 2336/4885LMNA 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.